Irinotecan Fresenius Kabi (Irinotecan Hydrochloride Trihydrate)

After infusion, Irinotecan is metabolised to SN‑38, which binds to DNA topoisomerase I. This stabilises the transient DNA‑enzyme complex, preventing the re‑ligation of single‑strand breaks during replication. The resulting DNA damage triggers apoptosis in rapidly dividing cancer cells.

The dose of Irinotecan is individualized by the prescribing oncologist based on factors such as body surface area, disease stage, prior therapies, and organ function. The prescriber determines the exact amount, infusion rate, and schedule in accordance with clinical guidelines and patient tolerance.

Safety data for Irinotecan during pregnancy and lactation are limited, and the drug is classified as contraindicated in pregnant women because of potential fetal harm. Breastfeeding is not recommended while receiving Irinotecan, as the medication may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a different mechanism from agents such as oxaliplatin (a platinum compound) or 5‑fluorouracil (a pyrimidine analogue). In combination regimens, Irinotecan can provide synergistic tumor control, especially in patients who have progressed on oxaliplatin‑based therapy, but it may have a higher incidence of diarrhea and neutropenia.

Irinotecan should be stored at controlled room temperature, typically below 25 °C, in its original packaging to protect it from light and moisture. Once reconstituted, the solution must be used within the time frame specified in the product label and kept refrigerated if required by the preparation instructions.

Irinotecan is supplied as a sterile powder for intravenous infusion. It is reconstituted with a compatible diluent, filtered, and administered by slow infusion over 30‑90 minutes, depending on the protocol. Administration is performed by trained medical staff in a clinical setting equipped for infusion therapy.

The most serious adverse events include severe neutropenia with fever, life‑threatening diarrhea that can lead to dehydration or colitis, hepatic toxicity, and rare allergic reactions. Prompt monitoring of blood counts, gastrointestinal symptoms, and liver function tests is essential to mitigate these risks.

Irinotecan is contraindicated in patients with known hypersensitivity to the drug or its excipients, those with severe bone‑marrow suppression (e.g., neutrophil count <1500 µL), uncontrolled infections, or significant hepatic impairment. Caution is also advised for patients with a history of severe gastrointestinal disorders.